HONG KONG, Feb. 9, 2026 /PRNewswire/ — Peijia Medical Limited (HKEX: 9996) today announced that it has formally submitted the European Union Medical Device Regulation (EU MDR) CE Mark registration application for its internally developed GeminiOne Transcatheter Edge-to-Edge Repair (TEER)…
Coronary/Structural Heart
AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care
The ALPHA-PE Research Fund Supports Independent, Physician-Led Studies to Advance Real-World PE Evidence LATHAM, N.Y.–Feb. 5, 2026– AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving patient quality of life, and […]
Cereno Scientific broadens development focus for CS014 to pulmonary hypertension associated with interstitial lung disease
GOTHENBURG, Sweden, Feb. 4, 2026 /PRNewswire/ — Cereno Scientific (NASDAQ First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that it is broadening the development focus…
Bristol Myers Squibb Introduces “Change the Target. Change What’s Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care
Cardiovascular and thromboembolic diseases are among the leading causes of death and disability, accounting for nearly 1 million deaths in the U.S. annually Clinician-focused educational program, developed in partnership with Johnson & Johnson, highlights care for patients at high risk of thromboembolic events such as stroke, and the emerging potential […]
RevealDx Receives FDA Clearance for AI Powered Lung Nodule Risk Assessment
Seattle, WA – February 3, 2026 – RevealDx, a leader in AI tools for the characterization of lung nodules, announced FDA clearance of RevealAI-Lung. The company had previously announced MDR Certification in November of 2025. The RevealDx technology characterizes incidental lung nodules by producing a Malignancy Similarity Index (mSI™), a […]
Lubrizol Launches Tolerathane™ Thermoplastic Polyurethane (TPU) for Implantable Medical Devices
CLEVELAND, OH – Lubrizol announces the launch of Tolerathane™ TPU, a new medical-grade material engineered to meet the evolving demands of implantable medical devices. Compared to other TPU materials, Tolerathane™ TPU offers unparalleled tolerance to harsh biological conditions while maintaining superior softness, mechanical resilience, and seamless integration into standard thermoplastics […]
SCAI Expert Opinion Explores ‘Wire-Free’ Angiography-Derived Physiology for Coronary Assessment
WASHINGTON—A new expert opinion from the Society for Cardiovascular Angiography & Interventions (SCAI) examines the evolving role of angiography-derived physiology (ADP), a wire-free method for coronary physiologic assessment that applies computational modeling or artificial intelligence (AI) to standard coronary angiographic images for the assessment and management of coronary artery disease. Published in JSCAI, “Angiography-Derived Physiology […]
HighLife Receives CE Mark Approval for its TMVR Solution
Paris, France, January 26, 2026 – HighLife SAS, a leading MedTech company focused on transcatheter solutions for structural heart disease, today announced that it has received CE Mark approval for the HighLife Transcatheter Mitral Valve Replacement (TMVR) System for the treatment of adult patients suffering from symptomatic moderate-severe or severe mitral valve regurgitation (MR), […]
The Lancet Publishes TRICORDER Study: Real-World Evaluation Shows Increased Detection When Eko AI-Enabled Stethoscopes Are Used in Primary Care
Large-scale NHS trial led by Imperial College London across 200+ NHS practices shows significant gains in early cardiac disease detection through AI-assisted stethoscope exams SAN FRANCISCO, Jan. 29, 2026 /PRNewswire/ — Eko Health, a leader in AI-powered cardiac and pulmonary disease…
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
ACES-EMB is the first randomized-controlled trial to compare dd-cfDNA surveillance to routine biopsy in organ transplantation, highlighting the benefits of Prospera™ in organ rejection AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial […]



